Following the initial DREAMM-7 readout and another positive phase 3 readout from the DREAMM-8 trial that’s pitting Blenrep ...
BMS is part of a wave of drug developers, both large and small, that hustled CD19-directed CAR-T cell therapies into ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...
AbbVie’s deal flop and NFL high-profile draft busts have a lot in common.
Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Bristol-Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Shares were recently up 11% after AbbVie reported ...
The third quarter of 2024 brought a mix of gains and modest declines for the pharmaceutical industry’s top players ... grew ...
Experts in the neuropsychiatry drug development space say targeting the right patient population will be key for success in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback